Novo Nordisk A/S
NOVO-B
Rankning i aktier
#109
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Aktiekurs
$39.24
Senast synkroniserad: 2026-10-21
Marknadsvärde
$173.16B
Förändring (1 dag)
-5.26%
Förändring (1 år)
-26.52%
Land
DK
Handel Novo Nordisk A/S (NOVO-B)
Kategori
Healthcare
EPS för Novo Nordisk A/S (NOVO-B)
EPS per December 2025 TTM: $3.62
Enligt Novo Nordisk A/Ss senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) $3.62. Vid slutet av 2026 hade bolaget ett EPS på 0, lika med EPS från 2026 som var 0.
EPS-historik för Novo Nordisk A/S från 2026 till 2026
EPS vid slutet av varje år
| År | EPS | Ändra |
|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | ||
EPS för liknande företag eller konkurrenter
| Företag | EPS | EPS-differens | Land |
|---|---|---|---|
| $29.89 | 725.53% |
US
|
|
| $6.60 | 82.29% |
US
|
|
| $3.55 | -1.95% |
US
|
|
| $1.26 | -65.20% |
US
|
|
| $20.39 | 463.12% |
CH
|
